AstraZeneca Buys Belgian EsoBiotec for Up to $1 Billion to Boost Cell-Therapy Portfolio
www.wsj.com
The deal includes the Belgian biotechs vivo cell-therapy platform, which modifies immune cells within the patients body, potentially increasing access to treatment and reducing costs.
0 Kommentare ·0 Anteile ·24 Ansichten